Literature DB >> 14608536

Cytogenetic findings in blastoid mantle cell lymphoma.

Joseph D Khoury1, Filiz Sen, Lynne V Abruzzo, Kimberly Hayes, Armand Glassman, L Jeffrey Medeiros.   

Abstract

A subset of mantle cell lymphoma (MCL) tumors has blastoid morphology, and a number of morphologic variants of blastoid MCL have been described in the literature. In this report, we document the cytogenetic findings in 27 cases of blastoid MCL. Conventional cytogenetic analyses were performed on bone marrow aspirates involved by MCL from 27 patients. There were 14 men and 13 women with a median age of 63 years (range, 40-79 years). Diagnostic tissue biopsy and bone marrow specimens were reviewed, and cases were divided into 2 morphologic groups: classic (12 cases) and pleomorphic (15 cases), as defined in the World Health Organization classification. All tumors had an immunophenotype compatible with MCL, were positive for cyclin D1, and carried the t(11;14). Twenty-four cases had complex karyotypes with 3 or more chromosomal abnormalities in addition to the t(11;14). In classic blastoid MCL, abnormalities of chromosomes 13, 18, and 8 were most common. In pleomorphic blastoid MCL, abnormalities of chromosomes 13, 17, and 3 were most frequent. Chromosome 22 abnormalities were detected exclusively in the pleomorphic group. Tumors in which the neoplastic cells showed prominent nucleoli had a significantly higher frequency of chromosome 17 abnormalities (P = 0.03). We conclude that blastoid MCL tumors often show complex cytogenetic aberrations. Some abnormalities correlate with morphologic features, suggesting that morphologic variants of blastoid MCL may arise via different molecular pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14608536     DOI: 10.1053/s0046-8177(03)00412-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  19 in total

1.  Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.

Authors:  Jeff D Wang; Samuel G Katz; Elizabeth A Morgan; David T Yang; Xueliang Pan; Mina L Xu
Journal:  Hum Pathol       Date:  2019-08-16       Impact factor: 3.466

2.  Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.

Authors:  K Sevcikova; Z Zhuang; G Garcia-Manero; R H Alvarez; H M Kantarjian; M Mego; C Albarracin; G Tang; S S Strom; L J Medeiros; G N Hortobagyi; J M Reuben; J D Khoury
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

Review 3.  Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.

Authors:  Narittee Sukswai; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

4.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

5.  TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

Authors:  Sanam Loghavi; Alyaa Al-Ibraheemi; Zhuang Zuo; Guillermo Garcia-Manero; Mariko Yabe; Sa A Wang; Hagop M Kantarjian; Cameron C Yin; Roberto N Miranda; Raja Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos; Joseph D Khoury
Journal:  Br J Haematol       Date:  2015-06-30       Impact factor: 6.998

6.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

7.  Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.

Authors:  Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

8.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

Authors:  Tapan M Kadia; Preetesh Jain; Farhad Ravandi; Guillermo Garcia-Manero; Michael Andreef; Koichi Takahashi; Gautam Borthakur; Elias Jabbour; Marina Konopleva; Naval G Daver; Courtney Dinardo; Sherry Pierce; Rashmi Kanagal-Shamanna; Keyur Patel; Zeev Estrov; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

9.  Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.

Authors:  Chi Young Ok; Vasiliki Leventaki; Sa A Wang; Courtney Dinardo; L Jeffrey Medeiros; Sergej Konoplev
Journal:  Am J Clin Pathol       Date:  2016-01-22       Impact factor: 2.493

Review 10.  Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

Authors:  Maria Sanz-De Pedro; Wei Wang; Rashmi Kanagal-Shamanna; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.